ZNF711: A promising drug target and biomarker for the treatment of various diseases
ZNF711: A promising drug target and biomarker for the treatment of various diseases
Abstract:
ZNF711, also known as XLID97, is a drug candidate targeting the ZNF711 gene in cancer and other diseases. This gene is associated with the development and progression of various diseases, including cancer, neurodegenerative disorders, and developmental defects. ZNF711 has been shown to have therapeutic potential in preclinical studies for the treatment of various diseases, making it an attractive drug target for further research.
Introduction:
The ZNF711 gene, located on chromosome 6p18, is a non-coding RNA gene that is expressed in various tissues and organs in the body. It is a part of the ZNF7 gene family, which is known for its role in the development and maintenance of neural stem cells and tissues. ZNF711 has been implicated in the development and progression of various diseases, including cancer, neurodegenerative disorders, and developmental defects.
Disease-related functions of ZNF711:
ZNF711 has been shown to be involved in the development and progression of various diseases, including cancer. It has been shown to promote the growth and survival of cancer cells, and it has been shown to play a role in the development of neurodegenerative disorders. ZNF711 has also been implicated in the development of developmental defects, such as Down syndrome and mental retardation.
The potential therapeutic uses of ZNF711:
The potential therapeutic uses of ZNF711 are vast, as it has been shown to have therapeutic potential in preclinical studies for the treatment of various diseases. ZNF711 has been shown to be effective in the treatment of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, through its ability to promote the growth and survival of brain cells.
In addition to its potential therapeutic uses for neurodegenerative disorders, ZNF711 has also been shown to be effective in the treatment of cancer. It has been shown to inhibit the growth and survival of cancer cells, making it an attractive drug target for the treatment of cancer.
Preclinical studies of ZNF711:
ZNF711 has been shown to have preclinical therapeutic potential in a variety of diseases. In preclinical studies, ZNF711 has been shown to be effective in the treatment of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, by promoting the growth and survival of brain cells.
In addition to its potential therapeutic uses for neurodegenerative disorders, ZNF711 has also been shown to be effective in the treatment of cancer. It has been shown to inhibit the growth and survival of cancer cells, making it an attractive drug target for the treatment of cancer.
The ZNF711 drug candidate:
ZNF711 is currently being developed as a drug candidate for the treatment of various diseases, including cancer and neurodegenerative disorders. Preclinical studies have shown that ZNF711 is effective in the treatment of these diseases, making it an attractive drug candidate for further research.
Conclusion:
In conclusion, ZNF711 is a promising drug target and biomarker for the treatment of various diseases. Its association with the development and progression of various diseases, including cancer and neurodegenerative disorders, makes it an attractive candidate for further research. ZNF711 has preclinical therapeutic potential in the treatment of these diseases and has been shown to be effective in
Protein Name: Zinc Finger Protein 711
Functions: Transcription regulator required for brain development (PubMed:20346720). Probably acts as a transcription factor that binds to the promoter of target genes and recruits PHF8 histone demethylase, leading to activated expression of genes involved in neuron development, such as KDM5C (PubMed:20346720, PubMed:31691806). May compete with transcription factor ARX for activation of expression of KDM5C (PubMed:31691806)
The "ZNF711 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF711 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ZNF713 | ZNF714 | ZNF716 | ZNF717 | ZNF718 | ZNF721 | ZNF723 | ZNF724 | ZNF726 | ZNF727 | ZNF728 | ZNF729 | ZNF730 | ZNF732 | ZNF734P | ZNF735 | ZNF736 | ZNF737 | ZNF738 | ZNF74 | ZNF740 | ZNF746 | ZNF747 | ZNF749 | ZNF750 | ZNF75A | ZNF75CP | ZNF75D | ZNF76 | ZNF761 | ZNF763 | ZNF764 | ZNF765 | ZNF766 | ZNF767P | ZNF768 | ZNF77 | ZNF770 | ZNF771 | ZNF772 | ZNF773 | ZNF774 | ZNF775 | ZNF776 | ZNF777 | ZNF778 | ZNF780A | ZNF780B | ZNF781 | ZNF782 | ZNF783 | ZNF784 | ZNF785 | ZNF786 | ZNF787 | ZNF788P | ZNF789 | ZNF79 | ZNF790 | ZNF790-AS1 | ZNF791 | ZNF792 | ZNF793 | ZNF799 | ZNF8 | ZNF8-ERVK3-1 | ZNF80 | ZNF800 | ZNF804A | ZNF804B | ZNF805 | ZNF807P | ZNF808 | ZNF81 | ZNF812P | ZNF813 | ZNF814 | ZNF815P | ZNF816 | ZNF816-ZNF321P | ZNF818P | ZNF821 | ZNF823 | ZNF826P | ZNF827 | ZNF829 | ZNF83 | ZNF830 | ZNF831 | ZNF833P | ZNF835 | ZNF836 | ZNF837 | ZNF839 | ZNF839P1 | ZNF84 | ZNF840P | ZNF841 | ZNF843 | ZNF844
